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Abstract 
Background: Some studies have suggested that patients with diabetes and foot complications have worse cardio-
vascular and cerebrovascular risk profiles, higher degrees of endothelial dysfunction and arterial stiffness and a higher 
inflammatory background than patients with diabetes without diabetic foot complications. Patients with diabetes 
mellitus have an alteration in the sympathovagal balance as assessed by means of heart rate variability (HRV) analysis, 
which is also related to the presence of endothelial dysfunction. Other studies suggest a possible role of inflammation 
coexisting with the alteration in the sympathovagal balance in favor of the atherosclerotic process in a mixed popula-
tion of healthy subjects of middle and advanced age.
Aims: The aim of this study was to evaluate the degree of alteration of sympathovagal balance, assessed by HRV 
analysis, in a cohort of patients with diabetes mellitus with diabetic foot and in control subjects without diabetic foot 
compared with a population of healthy subjects and the possible correlation of HRV parameters with inflammatory 
markers and endothelial dysfunction indices.
Methods: We enrolled all patients with diabetic ulcerative lesions of the lower limb in the Internal Medicine with 
Stroke Care ward and of the diabetic foot outpatient clinic of P. Giaccone University Hospital of Palermo between 
September 2019 and July 2020. 4-h ECG Holter was performed. The following time domain HRV measures were ana-
lyzed: average heart rate, square root of the mean of successive differences of NN (RMSSD), standard deviation or square 
root of the variance (SD), and standard deviation of the means of the NN intervals calculated over a five-minute period 
(SDANN/5 min). The LF/HF ratio was calculated, reactive hyperemia was evaluated by endo-PAT, and serum levels of 
vaspine and omentin-1 were assessed by blood sample collection.
Results: 63 patients with diabetic foot, 30 patients with diabetes and without ulcerative complications and 30 
patients without diabetes were enrolled. Patients with diabetic ulcers showed lower mean diastolic blood pressure 
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Background
Among diabetic vascular complications, foot ulcers are 
the major cause of hospitalization in patients with dia-
betes and a significant cause of health care costs (over 
20%–40% of health care resources have been reported to 
be related to foot care related to diabetes).
Several studies also indicate that foot ulcers in patients 
with diabetes are related to high mortality. In fact, dia-
betic foot is a major cause of morbidity in patients with 
diabetes, and the mortality rate is approximately double 
that of patients without a foot ulcer [1–4]. Some studies 
also suggest that patients with diabetes and foot compli-
cations, compared to patients with diabetes without dia-
betic foot complications, have a worse cardiovascular and 
cerebrovascular risk profile, a higher degree of endothe-
lial dysfunction and arterial stiffness and a greater inflam-
matory background [2, 3, 5].
Some authors also reported that patients with diabetes 
mellitus have an alteration in the sympathovagal balance 
assessed by means of heart rate variability (HRV) analy-
sis, which is also related to the presence of endothelial 
dysfunction [6]. Finally, other studies suggest a possible 
role of inflammation coexisting with the alteration in the 
sympathovagal balance favoring the atherosclerotic pro-
cess in a mixed population of healthy subjects of middle 
and advanced age [7, 8].
Nevertheless, a few studies [6, 7] have analyzed the 
degree of alteration of the autonomic nervous system in 
patients with diabetes and foot complications compared 
to patients with diabetes without diabetic foot complica-
tions. To the best of our knowledge, no study has evalu-
ated the possible association between the inflammatory 
background of patients with diabetic foot and alterations 
in the autonomic nervous system.
On this basis, the aim of our study was to evaluate 
whether patients with diabetes and foot ulcers present 
a higher degree of sympathovagal imbalance (in favor of 
activation of the sympathetic nervous system) than dia-
betic subjects without foot complications to highlight 
whether this alteration may be associated with a more 
extensive inflammatory pathway and a higher degree of 
endothelial dysfunction in these subjects than in those 
without complications.
Thus, the aim of this study project was to evaluate 
the degree of alteration of the sympathovagal balance, 
assessed by HRV analysis, in a cohort of patients with 
diabetes mellitus with diabetic foot and in control sub-
jects without diabetic foot compared with a population 
of healthy subjects and the possible correlation of HRV 
parameters with inflammatory markers and endothelial 
dysfunction indices.
Aims of the study
1. The first aim of our study was to evaluate the degree 
of autonomic nervous system dysfunction by analyz-
ing heart rate variability (HRV) in a cohort of patients 
with diabetes with and without foot complications 
compared to a sample of healthy control subjects.
2. The second aim was to evaluate any correlation 
between HRV parameters (SDNN and the LF/HF 
ratio) and adipoinflammatory dysfunction mark-
ers and endothelial dysfunction indices in the same 
cohort of patients.
Materials and methods
We enrolled all patients with diabetic ulcerative lesions of 
the lower limb of the diabetic foot outpatient clinic of the 
Surgery Department of P. Giaccone University Hospital 
of Palermo and those admitted to the Internal Medicine 
with Stroke Care ward of P. Giaccone University Hospital 
of Palermo between September 2019 and July 2020.
During this period, patients with diabetes with no 
mention of ulcerative complications were also recruited 
as controls afferent at our ward for clinical complications 
related to diabetes (glycometabolic decompensation, 
hypoglycemia, skin lesions) and a population of healthy 
controls without diabetes admitted to our ward for other 
causes.
values than healthy controls, lower MMSE scores corrected for age, lower serum levels of omentin-1, lower RHI values, 
higher body weight values and comparable body height values, HF% and LF/HF ratio values. We also reported a 
negative correlation between the RHI value and HRV indices and the expression of increased parasympathetic activity 
(RMSDD and HF%) in subjects with diabetic foot and a statistically significant positive correlation with the LF/HF ratio 
and the expression of the sympathovagal balance.
Discussion: Patients with diabetic foot show a higher degree of activation of the parasympathetic system, expressed 
by the increase in HF values, and a lower LF/HF ratio. Our findings may corroborate the issue that a parasympathetic 
dysfunction may have a possible additive role in the pathogenesis of other vascular complications in subjects with 
diabetic foot.
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All patients provided informed consent to take part in 
the study and for data disclosure in accordance with the 
principles of the 2001 Helsinki Declaration.
All patients with inflammatory or infectious dis-
eases, autoimmune and/or rheumatic diseases, neo-
plasms, hematological diseases, severe renal or hepatic 
insufficiency, fever, treatment with anti-inflammatory 
drugs, and recent hospitalization in the last month were 
excluded from the study.
Diabetic foot also called Diabetic foot syndrome (DFS) 
is defined, according to the WHO, as an ulcerative lesion 
of the foot (including the ankle) related to neuropathy 
and to different degrees of ischemia and infection [8]. 
Ulcerative foot injury is defined as a continuous lesion of 
the skin that takes more than 14 days to heal [9].
Each subject with diabetic foot will therefore be 
matched by age (± 3 years) and sex with a subject with-
out diabetic foot and a healthy subject.
Diabetic distal symmetric polyneuropathy (DSPN) was 
assessed by collecting the patient’s medical history, by 
clinical evaluation and by diagnostic tests such as pin-
prick and temperature sensation for evaluation of small-
fiber function and 10-g monofilament, and ankle reflex 
for Large-fiber function [10, 11]. DSPN was defined by 
the presence of symptoms and/or signs of peripheral 
nerve dysfunction in people with diabetes after the exclu-
sion of other cause [11].
To evaluate the symptoms of neuropathy, the Neuropa-
thy Symptom Score (NSS) [10] was used, which is gener-
ally used in clinical practice and has shown high validity 
and sensitivity [11].
A careful objective examination of the lower limb was 
carried out to look for the presence of the following char-
acteristics: hammer or claw foot, Charcot deformity, limit 
of the big toe, prominent metatarsal heads, hallux valgus, 
bony prominences and abnormal ankle angle. The big toe 
was measured with a goniometer.
The diagnosis of type 2 diabetes mellitus was based on 
the revised American Diabetes Association (ADA) cri-
teria, using random blood glucose values > 126  mg/dL 
or using a clinical algorithm that considered the age of 
onset, symptoms, present weight, family history, initia-
tion of insulin treatment and history of ketoacidosis [12].
Hypertension was defined using the ESC 2018 criteria 
[13].
Dyslipidemia was defined by triglyceride lev-
els ≥ 150  mg/dl and HDL cholesterol levels < 40  mg/dl 
based on the patient’s sex [14].
Laboratory analysis
Clinical and anthropometric data were collected at the 
time of enrollment. Patients were classified as obese 
(BMI ≥ 30  kg/m2), overweight (BMI 25–29.9  kg/m2), or 
normal weight (BMI 18.5–24.9 kg/m2).
At the time of enrollment, a blood sample was taken to 
assess the levels of ALT, triglycerides, blood sugar, total 
cholesterol and HDL cholesterol.
Evaluation of cognitive performance
The Mini-Mental State Examination (MMSE) was admin-
istered, and a questionnaire with 11 questions was used 
to evaluate the 6 major cognitive areas (language, atten-
tion, orientation, memorization, repetition and calcu-
lation). The maximum score is 30, while MMSE values 
below 24 (23 or lower) appear to be suggestive of “mild 
cognitive impairment” [15].
Evaluation of endothelial indices
The principle of RH-PAT has been previously described 
by some studies. Briefly, a blood pressure cuff was placed 
on an upper limb, while the contralateral arm was used 
as a control. The PAT probe was placed on one finger of 
each of the two hands. After a period of 5  min of con-
trol measurement, the blood pressure cuff was inflated to 
60  mmHg above the previously measured systolic pres-
sure or up to 200  mmHg for 5  min, after which it was 
deflated to induce reactive hyperemia. The RH-PAT data 
were analyzed digitally using the Endo-PAT2000 soft-
ware version 3.0.4. The RH-PAT index reflects the extent 
of reactive hyperemia and was calculated as the ratio of 
the mean PAT signal amplitudes above the first minute 
of initial measurement and 1.5 min of measurement after 
cuff deflation (A: control arm; C: occluded arm) divided 
by the average of the PAT signal amplitudes over a 2.5-
min period prior to inflation of the blood pressure cuff 
(B: control arm; D: occluded arm). This RH-PAT index, 
called the reactive hyperactivity index (RHI), is expressed 
by the formula RHI = (C/D)/(A/B) × basal correction.
Evaluation of the sympathovagal balance
For the execution of the 24-h ECG Holter, Sorin Spider-
view Digital Holter Recorder devices were used, and the 
analysis of the collected data was carried out through 
the ELA Medical SyneScope version 3.10 program. The 
device was placed between 8:30 and 9:30 in the morn-
ing and worn by the patient for 24 h. The Holter recorder 
involves the placement of ten electrodes in the precor-
dial region. During monitoring, the patient was asked 
to carry out normal daily activity while avoiding intense 
physical exercise. The trace was recorded on a special 
card contained in the device and subsequently analyzed 
on the computer through 3 recording channels. The 
analysis, carried out by a single operator trained in the 
use of the software, initially provided for the distinction 
between artifacts, normal beats and ventricular beats 
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and, subsequently, the assessment by the operator of the 
events selected by the computer.
By event, we mean:
– Minimum and maximum RR
– Minimum and maximum HR
– Supraventricular tachycardia (SVT) (HR > 150 bpm)
– Ventricular tachycardia (TV) (HR > 50 bpm)
– Bradycardia (HR < 45 bpm)
– Pause (NN greater than 2500 ms)
– Missing beats
– Supraventricular (SVBE) and ventricular (EVB) 
ectopic beats, single, in
– Couple and in short run (three to fifteen beats)
– SVBE and EVB at two or three times
– Instability NN
– Acceleration and/or deceleration NN
The operator reserved the right to reevaluate the 
remaining part of the track, even if one or more events 
were not automatically detected, for the correct 
classification.
ECG Holter monitoring was considered invalid in the 
following cases:
– Recording duration < 22 h
– Number of artifacts and ectopic beats > 20% of the 
total number of beats (in the presence of ectopic 
beats, both the NN interval represented by the cop-
ula and that represented by the post-extrasystolic 
pause were excluded from the final analysis)
– For each monitoring, the HRV measurements of the 
time domain and frequency in the day (8–21 h), night 
(23–6 h) and 24 h were taken into consideration.
– The following time domain HRV measures were ana-
lyzed:
– Average heart rate
– Square root of the mean of successive differences of 
NN (RMSSD)
– Standard deviation or square root of the variance 
(SD)
– Standard deviation of the means of the NN 
intervals calculated over a five-minute period 
(SDANN/5 min).
– The following frequency domain HRV measures were 
analyzed:
– High frequency (0.15–0.4 Hz) (HF%)
– Low frequency (0.04–0.15 Hz) (LF%)
– LF/HF ratio: ratio of Low Frequency to High Fre-
quency.
Biochemical analysis
As expression of adipo-inflammatory dysfunction, serum 
levels of vaspine and omentin-1 were assessed by blood 
sample collection. The serum was obtained by centrifu-
gation at 3000 rpm for 10 min and stored at a tempera-
ture of −80  °C. All samples were analyzed in the same 
analytical session. Vaspine serum concentrations were 
measured using an ELISA kit (BioVendor, BioVendor 
Laboratory Medicine, Inc. Czech Republic) (detection 
range: 0.1–1000 ng/ml; sensitivity: < 1 ng/ml). The serum 
levels of omentin-1 were evaluated using an ELISA kit 
(Human Omentin EIA, Raybiotech) (detection range: 
0.031–2 ng/ml; sensitivity: 0.01 ng/ml Atlanta, USA).
Statistical analysis
Quantitative and qualitative statistical analyses of the 
data, including descriptive statistics, were performed 
for all items. Continuous variables are expressed as the 
mean values ± standard deviations (SDs), unless other-
wise specified. The basic significant differences between 
the groups were evaluated using the chi-square test or 
Fisher’s test, as needed, for the categorical variables. The 
univariate analysis of variance (ANOVA) was performed 
for parametric variables, and post hoc analysis with the 
Tukey test was used to determine whether there were 
pairwise intragroup differences. Multivariable logistic 
regression analysis examined the correlation between 
patient characteristics (independent variables as demo-
graphic and clinical variables resulted significant at uni-
variate analysis), and patient groups (dependent variable, 
diabetic subjects and subjects with diabetic foot versus 
healthy subjects). In addition, odds ratios (ORs) and 
their 95% confidence intervals (CIs) were calculated and 
adjusted for drug therapy as a covariate. Pearson’s corre-
lation analysis was conducted to evaluate the association 
between endothelial dysfunction indices and the clinical-
laboratory-instrumental alteration variant in the various 
groups. Data were analyzed using SPSS Software version 
22.0 (IBM Corp., Armonk, NY, USA). P-values below 
0.05 were considered statistically significant.
Results
Between September 2019 and August 2020, 63 patients 
with diabetic foot were enrolled at the Internal Medi-
cine with Stroke Care ward of the University Hospital of 
Palermo (Italy).
We also enrolled a control group of 30 patients with 
diabetes and without ulcerative complications and 30 
patients without diabetes admitted to our internal medi-
cine ward for causes other than diabetes or its related 
complications.
The laboratory, demographic and general variables of 
patients with diabetes with and without ulcerative foot 
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ulcer lesions and healthy control subjects are presented 
in Table 1.
Diabetic subjects with ulcerative lesions of the lower 
limb showed higher body height values than the dia-
betic controls (168.33 ± 7.19  cm vs 161.97 ± 20.12  cm; 
p = 0.042) and HF (21.23 ± 14.68 vs 11.10 ± 11.58; 
p = 0.002), lower values of the LF/HF ratio (1.63 ± 1.66 vs 
3.18 ± 2.82; p = 0.001), and lower RHI values (1.60 ± 0.33 
vs 2.01 ± 0.69; p < 0.0005), lower serum levels of omen-
tin (18.95 ± 3.30 ng/ml vs 21.80 ± 5.79 ng/mL; p = 0.014) 
and comparable mean diastolic blood pressure values 
(71.14 ± 11.30 mmHg vs 75.33 ± 10.08 mmHg; p = 0.262) 
and body weight (84.25 ± 14.10  kg vs 87.10 ± 27.82; 
p = 1.00) (see Table 2).
Patients with diabetic ulcers compared to healthy 
controls showed lower mean diastolic blood pres-
sure (71.14 ± 11.30  mmHg vs 77.66 ± 11.04  mmHg; 
p = 0.025), lower MMSE scores corrected for age 
(26.77 ± 3.44 vs 28.14 ± 1.15; p = 0.038), lower serum lev-
els of omentin (18.95 ± 3.30 ng/ml vs 31.16 ± 4.53 ng/ml; 
p = 0.001), lower RHI values (1.60 ± 0.33 vs 2.20 ± 0.38; 
p = 0.00), higher body weight values (84.25 ± 14.10 kg vs 
73.06 ± 9.92; p = 0.05) and comparable body height val-
ues (168.33 ± 7.19  cm vs 163.933 ± 5.74  cm; p = 0.263), 
HF% (21.23 ± 14.68 vs 14.70 ± 11.15; p = 0.82) and LF/HF 
ratios (1.63 ± 1.66 vs 1.07 ± 0.44; p = 0.59) (see Table 2)..
Diabetic control patients showed lower serum lev-
els of omentin (21.80 ± 5.79  ng/ml vs 31.16 ± 4.53  ng/
ml; p < 0.0005), higher LF/HF ratio values (3.18 ± 2.82 
vs 1.07 ± 0.44; p < 0.0005), comparable RHI values 
(2.01 ± 0.69 vs 2.20 ± 0.38; p = 0.315), comparable age-
corrected MMSE scores (27.16 ± 2.38 vs 28.14 ± 1.15; 
p = 0.499) and comparable mean diastolic blood pressure 
values (75.33 ± 10.08  mmHg vs 77.66 ± 11.04  mmHg; 
p = 1.00) compared to the healthy controls (see Table 2).
Multiple regression analysis with the regard of diabetic 
foot presence (DFS) compared to healthy control sub-
jects showed a significant negative association between 
diabetic foot and serum levels of omentin (B = − 0.56; 
p < 0.0005) and a positive association between diabetic 
foot and hypertension (B = 3.96; p = 0.01) (see Table 3).
Multiple regression analysis with regard of diabetes 
without foot ulcerations (Non DFS) compared to healthy 
control subjects showed a significant negative asso-
ciation between Non DFS and serum levels of omentin 
(B =− 0.31 p < 0.003) and a positive association between 
Non DFS and LH/HF (B = 1.50; p = 0.03) (see Table 3).
Multiple regression analysis with regard of diabetic 
foot presence (DFS) vs diabetes without foot ulcerations 
showed a significant positive association between male 
sex and DFS (B = 4.17, p < 0.0005) and a negative asso-
ciation between DFS and omentin (B = − 0.24; p = 0.009) 
and peripheral artery disease (B. − 0.13; p: = 0.002). AND 
RHI (B = − 2.65; p = 0.007)  (see Table 4).
Pearson’s correlation analysis in patients with dia-
betic foot (DFS) showed a statistically significant nega-
tive correlation between the RHI and RMSDD (Pearson 
index − 0.47; p = 0.0001), SD (Pearson index − 0.374; 
p = 0.002), and HF% (Pearson index − 0.395; p = 0.001) 
and a statistically significant positive correlation between 
Table 1 Demographic and clinical variables in healthcare subjects and patients with or without diabetic foot
DFS, diabetes foot syndrome; ARBs, Angiotensin II receptor blockers
GLP-1: Glucagon-like peptide-1 receptor; DPP4 inhibitors, Inhibitors of dipeptidyl peptidase 4
a p, intergroup differences among patient groups (chi-square test or Fisher’s test, as needed)
Variables DFS (n = 63) NDFS (n = 30) Healthy (n = 30) pa
Sex M/F 45/18 11/19 14/16 0.003
Hypertension (n/%) 58/92 24/80 14/46  < 0.0005
Cardiovascular events (n/%) 24/38 12/40 20/66 0.028
Stroke (n/%) 13/20 4/13 3/10 0.380
Dyslipidemia (n/%) 45/71 18/60 24/80 0.231
Smoker (n/%) 23/36 10/33 25/83  < 0.0005
Beta blocker (n/%) 20/31 13/43 12/40 0.503
Calcium channel blocker (n/%) 27/42 13/43 12/40 0.958
ACE inhibitor or ARBs (n/%) 26/41 13/43 12/40 0.965
Statin (n/%) 47/74 20/66 25/83 0.331
Antiplatelet (n/%) 28/44 10/33 13/43 0.580
GLP-1 agonist or DPP4 inhibitors (n/%) 1/1 5/16 0/0 0.002
Sulfonylurea (n/%) 1/1 11/36 0/0  < 0.0005
Metformin (n/%) 10/15 16/53 0/0  < 0.0005
Insulin (n/%) 63/100 6/20 0/0  < 0.0005
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the RHI and the LF/HF ratio (Pearson index 0.280; 
p = 0.026) (see Table 5).
Discussion
In our current study, we analyzed the relationship 
between diabetic foot ulcers and sympathovagal balance. 
Only a few studies have evaluated the sympathovagal bal-
ance through HRV analysis in patients with diabetic foot 
[7]. Furthermore, there are few studies that have evalu-
ated surrogate indices of cardiovascular disease, such as 
endothelial function indices and serum levels of inflam-
matory adipokines, in a diabetic population with ulcera-
tive lesions of the lower limbs [1–3].
Some studies by our own group analyzed endothelial 
dysfunction and adipose inflammatory markers such 
as omentine and vaspin in subjects with diabetic foot in 
Table 2 Univariate analysis results in healthcare subjects compared to patients with and without diabetic foot
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; RHI, reactive hyperemia index; MMSE, Mini Mental State Examination; RMSSD, root 
mean square of the successive differences in 5 min; SDNN, standard deviation of the NN (R-R) intervals; SD, standard deviation; LF, low frequency; HF, high frequency; 
LF/HF, low frequency/high frequency
a p, intergroup differences among patient groups, univariate analysis of variance (ANOVA) and post hoc analysis with the Tukey test to determine pairwise intragroup 
differences
b vs healthy subjects, cvs NDFS
Variables DFS (n = 63) NDFS (n = 30) Healthy (n = 30) pa
Age (years) (mean ± SD) 66.57 ± 9.54 61.20 ± 9.40 64.83 ± 6.48 0.08
SBP (mmHg) (mean ± SD) 132.81 ± 13.81 130.83 ± 17.62 128.00 ± 10.38 0.39
DBP (mmHg) (mean ± SD) 71.14 ± 11.30b 75.33 ± 10.08 77.66 ± 11.04 0.02
Height (cm) (mean ± SD) 168.33 ± 7.19c 161.96 ± 20.12 163.93 ± 5.74 0.03
Weight (kg) (mean ± SD) 84.25 ± 14.10b 87.10 ± 27.82b 73.06 ± 9.92 0.005
BMI (kg/m2) (mean ± SD) 29.54 ± 4.23 30.78 ± 6.67 28.08 ± 4.19 0.11
RHI (mean ± SD) 1.60 ± 0.33bc 2.01 ± 0.69 2.20 ± 0.38  < 0.0005
MMSE (mean ± SD) 26.77 ± 3.44 27.03 ± 2.53 27.96 ± 1.24 0.16
MMSE corrected for age (mean ± SD) 26.57 ± 3.33b 27.16 ± 2.38 28.14 ± 1.15 0.03
HbA1c (%) (mean ± SD) 8.07 ± 1.26 7.74 ± 1.71 – 0.29
RMSDD (ms) (mean ± SD) 81.46 ± 95.22 46.23 ± 53.93 86.11 ± 74.04 0.10
SDNN/5 min (ms) (mean ± SD) 66.39 ± 23.97 59.40 ± 16.19 71.75 ± 22.52 0.09
SD (ms) (mean ± SD) 87.83 ± 50.65 85.69 ± 37.72 101.38 ± 47.07 0.34
LF% (mean ± SD) 19.63 ± 11.08 24.06 ± 13.64 55.35 ± 222.94 0.33
HF% (mean ± SD) 21.23 ± 14.68c 11.10 ± 11.58 14.70 ± 11.15 0.002
LF/HF (mean ± SD) 1.63 ± 1.66c 3.18 ± 2.82b 1.07 ± 0.44  < 0.0005
Omentin-1 (ng/mL) (mean ± SD) 18.95 ± 3.60bc 21.80 ± 5.79b 31.16 ± 4.53  < 0.0005
Vaspine (mean ± SD) 0.20 ± 0.05 0.21 ± 0.58 0.19 ± 0.03 0.23
Table 3 Multiple regression analysis in patients with and without DFS compared to healthcare subjects
Reference: Healthy subjects
DFS, diabetic foot syndrome; RHI, reactive hyperemia index; MMSE, Mini Mental State Examination; RMSSD HF, high frequency; LF/HF, low frequency/high frequency
Variables DFS Non DFS
B p Exp (B) 95% CI per Exp(B) B p Exp(B) 95% CI per Exp(B)
RHI − 2.10 0.15 0.12 0.007–2.15 0.55 0.64 1.74 0.16–18.07
Hypertension 3.96 0.01 52.64 2.14–1293.08 2.25 0.13 9.53 0.51–177.74
Cardiovascular events − 2.32 0.12 0.09 0.005–1.83 − 1.89 0.19 0.150 0.009–2.62
Smoker − 1.52 0.27 0.21 0.01–3.37 − 0.65 0.62 0.52 0.03–7.28
MMSE corrected for age − 0.23 0.48 0.79 0.40–1.53 − 0.18 0.58 0.82 0.427–1.60
HF% 0.53 0.43 1.05 0.92–1.20 − 0.002 0.93 0.99 0.87–1.13
LF/HF (%) 1.25 0.86 3.48 0.43–0.74 1.50 0.03 4.50 1.14–18.24
Omentin-1 (ng/mL) − 0.56  < 0.0005 0.56 0.437–0.742 − 0.31 0.003 0.72 0.58–0.89
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comparison with those without foot ulcerations [3, 5]. In 
this actual study we confirmed our previous findings con-
cerning the lower serum levels of omentin-1 lower and 
the lower median RHI values of subjects with diabetic 
foot. We also report the association between diabetic 
foot and omentin-1 and reactive hyperaemia index (RHI) 
as marker of endothelial dysfunction.
Nevertheless, to the best of our knowledge, no study 
has yet correlated endothelial dysfunction, assessed non-
invasively by means of the RHI, with dysfunction of the 
autonomic nervous system, assessed by the analysis of 
HRV, and serum levels of some inflammatory adipokines 
in a population of patients with diabetes and foot ulcers.
Aso et  al. [16] evaluated the sympathovagal balance 
obtained by means of the spectral analysis of HRV in a 
population with diabetic foot. In the population exam-
ined by Aso, the LF/HF ratio, representing the expres-
sion of the sympathovagal balance, was not particularly 
increased, although both the LF (sympathetic activation 
indices) and the HF (parasympathetic activation indices) 
were decreased.
Our study showed that patients with diabetic foot show 
a higher degree of activation of the parasympathetic sys-
tem, expressed by the increase in HF values, compared 
to diabetic controls and a lower LF/HF ratio compared 
to diabetic controls. The values of the LF/HF ratio of 
patients with DFS indicate a sympathovagal balance 
trending toward a higher degree of parasympathetic acti-
vation [17], albeit not statistically significant, consistent 
with the findings reported by Aso [16].
Takashy et  al. [18] noted that patients with diabetes 
with neuropathy had significant sympathetic dysfunction. 
Within the pathogenesis of diabetic ulcers, in addition 
to the already established role of diabetic micro- and 
macroangiopathy and the impairment of the somatic 
nervous system, dysfunction of the autonomic nervous 
system plays an important role. Sympathetic dysfunction 
involves sweating, dryness of the skin and a reduction in 
skin thickness, which leads to susceptibility to infections 
and the formation of a diabetic ulcer from mechanical-
compressive damage. Ahmed et  al. [19] showed that in 
patients with diabetic foot, the parasympathetic system is 
compromised early, which is then followed, over time, by 
permanent sympathetic dysfunction. Our actual results, 
depicting greater parasympathetic activation, can be 
explained by a counterbalance of the vagal action against 
a reduced sympathetic action.
Our study also highlighted a statistically significant 
negative correlation between the RHI value and HRV 
indices and the expression of increased parasympathetic 
activity (RMSDD and HF%) in subjects with diabetic foot 
and a statistically significant positive correlation with the 
LF/HF ratio and the expression of the sympathovagal bal-
ance. Endothelial dysfunction, due to excessive oxidative 
stress and a reduction in NO values, involves the inability 
of the endothelium to dilate following inducible ischemic 
stimuli. Endothelial dysfunction and reduced sympa-
thetic activity are closely related in the pathogenesis of 
diabetic ulcers, as endothelial dysfunction and the con-
sequent microangiopathy of the vasa nervorum involve 
a downregulation of the small autonomic-sympathetic 
fibers present in the periphery. This association has also 
been demonstrated in both healthy and hypertensive 
subjects by Pinter [20] and Tomiyama [21], respectively.
Table 4 Multiple regression analysis in patients without DFS compared to patients with DFS
Reference: NDFS
DFS, diabetic foot syndrome; RHI, reactive hyperemia index; MMSE, Mini Mental State Examination; RMSSD, root mean square of the successive differences; HF, high 
frequency
LF/HF, low frequency/high frequency; NDFS, non diabetic foot syndrome: diabetic subjects without foot ulcerations
Variables DFS
B p Exp(B) 95% CI for Exp(B)
Sex 4.17  < 0.0005 64.9 7.7−546.8
Peripheral arterial disease (mmHg) −  0.13 0.002 0.87 0.80−0.95
Weight (kg) − 0.03 0.10 0.96 0.92−1.08
RHI − 2.65 0.007 0.07 0.01−0.48
Hypertension 1.70 0.15 5.52 0.51−59.2
Cardiovascular events − 0.42 0.57 0.65 0.15−2.84
Smoker − 0.87 0.27 0.42 0.09−2.02
MMSE corrected for age − 0.04 0.76 0.95 0.69−1.30
HF (Hz) 0.05 0.17 1.06 0.98−1.14
LF/HF (%) − 0.25 0.23 0.77 0.51−1.18
Omentin-1 (ng/mL) − 0.24 0.009 0.78 0.65−0.94
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Few studies have correlated HRV variables and 
endothelial dysfunction indices. In a previous study 
by Bedile Irem Tiftikcioglu et  al. [22], the correlation 
between HRV and the RHI was analyzed, but this rela-
tionship was not statistically significant. This relationship 
could be explained by the influence exerted by microan-
giopathy on autonomic neuropathy. Hyperglycemia can 
cause changes in the intracellular redox state through the 
depletion of the cellular NADPH pool. Nonenzymatic 
glycosylation of proteins and macromolecules second-
ary to chronic hyperglycemia causes a greater tendency 
toward oxidative stress and high levels of oxidized lipo-
proteins (LDL in particular). High levels of fatty acids 
and hyperglycemia have both been shown to cause an 
increase in the oxidation level of phospholipids and pro-
teins, resulting in an increased prothrombotic tendency, 
as well as increased platelet aggregation. Numerous pro-
spective studies evaluating endothelial dysfunction in 
patients with diabetes indicate that it is closely associated 
with microangiopathy and macroangiopathy [23].
Our finding concerning a positive correlation between 
the RHI and the LF/HF ratio is therefore a possible origi-
nal finding, as well as the negative correlation between 
the RHI and the parasympathetic function indices. It is 
possible to assume that the persistent reduction in sym-
pathetic activity in patients with diabetic foot can be 
compensated for at the expense of greater parasympa-
thetic activity to recover the delicate homeostasis of the 
sympathovagal balance.
Our results did not highlight any particular differ-
ence between the percentages of HF and the LF/HF ratio 
between patients with diabetic foot and healthy patients. 
A possible explanation is that a discrete percentage of 
subjects in the control group suffered from chronic 
ischemic heart disease with consequent use of beta 
blockers, which caused an increase in parasympathetic 
activity.
Another interesting result that emerged from our 
study is the high LF/HF ratio in patients with diabetes 
compared to DFS and healthy controls. Some studies 
evaluated HRV in patients with diabetes with or with-
out microvascular complications [22–24]. In most cases, 
the LF/HF ratio appears to be decreased, especially in 
patients with diabetic neuropathy [22–24]. Min-Young 
Chun et  al. [25] assessed that worsening of autonomic 
neuropathy is positively correlated with the consensual 
reduction in the LF/HF ratio. Eckberg et al. [26] suggested 
that in the pathogenesis of diabetic neuropathy, there is 
early and early dysfunction of the parasympathetic sys-
tem, which is followed by a reduction in the sympathetic 
system. Me Ahmed et al. [19] proposed a similar patho-
genesis within the context of diabetic neuropathy compli-
cated by diabetic foot. Our diabetic cohort examined did 
not show numerous cases of diabetic neuropathy; thus, 
it is possible that the LF/HF ratio is increased, indicating 
an imbalance toward sympathetic activation, precisely 
due to the early initial parasympathetic dysfunction that 
characterizes diabetes and that can lead to a rather com-
mon microvascular complication such as diabetic neu-
ropathy. Our results show that patients with diabetic 
foot show significantly lower RHI values and therefore a 
greater degree of endothelial dysfunction than patients 
with diabetes without ulcers and healthy controls. Previ-
ously, Siasos et al. [27] provided the first evidence regard-
ing the correlation of diabetic ulcerative lesions with 
endothelial dysfunction. In a recent study by our own 
Table 5 Pearson correlation between the RHI and other 
variables in patients with DFS
RHI, reactive hyperemia index; MMSE, Mini Mental State Examination; RMSSD, 
root mean square of the successive differences in 5 min; SDNN, standard 
deviation of the NN (R–R) intervals; SD, standard deviation; LF, low frequency; HF, 
high frequency; LF/HF, low frequency/high frequency
RHI
RHI Pearson Correlation 1
Sig. (2-tailed)
N 63
MMSE corrected for age Pearson Correlation − 0.047
Sig. (2-tailed) 0.717
N 63
RMSSD (ms) Pearson Correlation 0.470
Sig. (2-tailed) 0.0001
N 63
SDANN5 MIN (ms) Pearson Correlation − 0.158
Sig. (2-tailed) 0.216
N 63
SD (ms) Pearson Correlation 0.374
Sig. (2-tailed) 0.002
N 63
LF (%) Pearson Correlation 0.022
Sig. (2-tailed) 0.862
N 63
HF (%) Pearson Correlation 0.395
Sig. (2-tailed) 0.001
N 63
LF/HF Pearson Correlation 0.280
Sig. (2-tailed) 0.026
N 63
Omentin-1 (ng/ml) Pearson Correlation 0.067
Sig. (2-tailed) 0.602
N 63
Vaspine Pearson Correlation − 0.151
Sig. (2-tailed) 0.237
N 63
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group [5], we reported that patients with diabetic foot 
had a higher degree of endothelial dysfunction, expressed 
as lower RHI values, compared to patients with diabetes 
and a control group of healthy patients. A greater degree 
of arterial stiffness was also found through the analysis 
of PWV and a greater degree of “mild cognitive impair-
ment”, as assessed by the MMSE scores.
Diabetic foot syndrome (DFS) represents a micro and 
macrovascular complication of diabetes. Endothelium-
dependent vasodilation is markedly impaired in the 
arteries of patients with hypertension, diabetes, ventric-
ular hypertrophy and other cardiovascular risk factors 
[28–32]. Therefore, both the micro- and macrovascular 
complications of diabetes are well represented by the 
evaluation of the indices of endothelium-dependent vas-
odilation, such as the RH-PAT index.
Our results showing significantly lower RHI levels in 
a cohort of patients with diabetic foot compared with a 
population of patients with diabetes and healthy controls 
are therefore in line with our previous studies [3, 5] and 
demonstrate that endothelial dysfunction evaluated with 
a noninvasive method can be considered a surrogate car-
diovascular risk marker.
In a recent cross-sectional observational study [33], 
conducted on the cohort of patients in the ADELAHYDE 
has been reported the association of arterial changes 
(arterial hypertrophy and stiffness, endothelial dysfunc-
tion) with cognition indexes Artery thickness and stiff-
ness as well as endothelial function should be measured 
simultaneously and may represent an additional target 
for the prevention of memory impairment and WMHs.
In a very recent study by our group [34], worse cogni-
tive performance, a higher prevalence of hyperintense 
lesions of the white matter on brain MRI, increased 
PWV values and reduced serum levels of omentin-1 were 
reported in patients with DFS compared to a diabetic 
population without ulcers, a healthy population with 
vascular ulcers and a control population. These patients 
also had low RHI levels compared to a healthy population 
with or without mention of a vascular ulcer and compa-
rable RHI values compared to patients with diabetes.
In our study, we have also reported how patients with 
diabetic foot, compared to diabetic controls without 
ulcers and healthy controls, have significantly lower 
serum levels of omentin-1. Recently, in agreement with 
the results of our group [34], Yamawaki et al. showed how 
omentin has a vasodilating effect on isolated blood ves-
sels, increasing the production of endothelium-derived 
NO [35]. The negative association between omentin, 
circulating IL-6 and C reactive protein was also shown 
to be related to endothelial dysfunction [36]. The inflam-
matory state associated with obesity-induced metabolic 
disorders [37] could be the cause of the dysfunction of 
endothelial cells in the blood vessels of visceral abdomi-
nal tissues, decreasing the expression and production of 
omentin. Proinflammatory cytokines (TNF-α and IL-6) 
proportionally indirectly correlate with circulating omen-
tin concentrations [38]. Furthermore, reduced concen-
trations of omentin in the synovial fluid of patients with 
rheumatoid arthritis have been described [39]. Inflam-
mation has been widely characterized as an important 
contributing factor to vascular endothelial dysfunction 
[40]. Cytokines could induce vasoconstriction by reduc-
ing the expression of endothelial NO synthase, reducing 
the bioavailability of NO and inducing the synthesis of 
endothelin-1 [41, 42]. Reduced expression of omentin in 
omental fat endothelial cells in patients with visceral obe-
sity may reflect the dysfunction of these cells caused by 
an obesity-associated proinflammatory state and oxida-
tive stress.
Thus, the concentration of circulating omentin in 
patients with IGT could be a useful biomarker of 
endothelial function.
Vaspine is an inflammatory adipokine produced by 
visceral and subcutaneous human adipose tissue [43] 
and appears to act on the adipoinsulin axis and to be 
associated with insulin resistance, especially in patients 
with type 2 diabetes mellitus [44]. Although vaspine has 
shown its ability to improve glucose tolerance and insulin 
sensitivity in mice, in humans, it seems to be positively 
associated with obesity-related diseases [45]. Some evi-
dence shows that vaspine levels can change according 
to the progression of diabetic disease; in particular, they 
increase at the onset of the disease and decrease later on 
[46].
Our results showing non significant differences 
between the three groups of vaspine serum levels and the 
significantly lower serum levels of omentin-1 in patients 
with diabetic foot compared to diabetic and healthy con-
trols can be explained by the different pathogenetic roles 
of these two adipokines in the context of microvascular 
foot damage. A recent study [47] reported a significant 
correlation between serum vaspine levels and leptin 
concentrations, indicating that serum vaspine levels are 
a reflection of the amount of human adipose tissue and 
that vaspine may play a compensatory role in insulin 
resistance, the main pathogenesis of diseases related to 
obesity. Our diabetic foot patients, compared to diabetic 
and healthy controls, had comparable BMI values and 
more or less equal body weights, which may be sufficient 
to explain why serum vaspine concentrations did not 
vary among the three groups.
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Limitations
The cross-sectional analysis is a limitation because it 
does not allow conclusions on cause–effect relation-
ships, and the relatively small sample size may also limit 
conclusions.
Conclusions
Thus, we can conclude that evaluation of heart rate 
variability (HRV) may be advisable in patients with dia-
betic foot because the presence of foot complications 
in these subjects seems to make these patients more 
prone, in comparison with subjects with diabetes with-
out foot complications other vascular complications 
[48]. Our findings may corroborate the issue that a par-
asympathetic dysfunction may have a possible additive 
role in the pathogenesis of other vascular complications 
in subjects with DFS.
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